14Feb/13

Theradiag's new biotherapy monitoring kits receive CE mark approval – News-Medical.net

Theradiag’s new biotherapy monitoring kits receive CE mark approval
News-Medical.net
Theradiag (ISIN: FR0004197747, Ticker: ALTER), a company specializing in theranostic and in vitro diagnostics, today announced it has obtained a CE mark for two new biotherapy monitoring kits; Tocilizumab (anti-IL6R) and Rituximab (anti-CD20) that

and more »